Activating JAK2 mutations in other haematological malignancies, such as myeloproliferative neoplasms, have demonstrated the clinical relevance of this gene and drawn more attention to its potential involvement in T-cell lymphoblastic leukaemia/lymphoma [19–21]. The gene discussed is JAK2; the disease is myeloproliferative neoplasm.